Roche launches comprehensive genomic profiling kit
December 2021—Roche has launched the Avenio Tumor Tissue Comprehensive Genomic Profiling Kit, complementing the current CGP portfolio offered by Roche and Foundation Medicine.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Bio-Plex Pro IgA, IgM SARS-CoV-2 panels
December 2021—Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The two new panels along with the company’s existing Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex panel aim to assist researchers in developing vaccines and to help public health researchers who perform seroprevalence studies based on serology specimens identify individuals who may have been exposed to SARS-CoV-2.
FDA approves QuantiFeron-TB Gold Plus on Liaison XS
December 2021—Qiagen announced that the FDA has approved the Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin’s automated Liaison XS platform. The Liaison QuantiFeron-TB Gold Plus tests for interferon gamma released from T cells that have encountered TB. The assay was developed by Qiagen and DiaSorin to offer streamlined laboratory automation for latent TB screening.
PixCell Medical opens U.S. subsidiary in Denver
December 2021—PixCell Medical (Yokne’am Illit, Israel) announced it has opened a U.S. subsidiary in the Denver metropolitan area. The new office aims to increase logistical and commercial support for the company’s U.S. clients and will handle order fulfilment across the country as well as provide additional clinical and technical support to customers.
Sysmex TH-11 urinalysis decapper unit
December 2021—Sysmex introduced its TH-11 Urine Sample Decapper Unit, which is designed to be used in conjunction with the Sysmex UN-Series Automated Urinalysis Solution. The unit is intended to eliminate manual decapping work, which can reduce workplace repetitive injuries, streamline work processes, and reduce exposure to biological hazards. The TH-11 comes in desktop or wagon modules.
FDA grants EUA for Lighthouse COVID-19 assay
December 2021—Lighthouse Lab Services announced that the FDA has granted emergency use authorization for its CovidNow SARS-CoV-2 assay kit. The EUA covers use for symptomatic and asymptomatic patients with a provider’s order.
Olympus announces first results of AI-based Dx tool for gastric cancer
December 2021—The results of Olympus’ ongoing joint research program to create an AI-based pathology diagnostic tool were announced at the Japan Society of Digital Pathology Study annual meeting. The AI tool was able to achieve 100 percent sensitivity and 50 percent or higher specificity for all gastric biopsy pathology specimens analyzed from the six facilities participating in the study.
Bio-Rad RP positive run control for SARS-CoV-2
December 2021—Bio-Rad announced its Exact Diagnostics RP Positive Run Control for syndromic respiratory panels is now available with inactivated whole virus for SARS-CoV-2. The unassayed external quality control contains 23 respiratory analytes in one vial and is intended to monitor the performance of clinical respiratory assays. The control is a combination of whole, intact virus and bacteria that have been heated or chemically inactivated and synthetic RNA transcripts.
LumiraDx COVID-19 antigen test gets expanded EUA
December 2021—LumiraDx announced that the FDA’s emergency use authorization for its SARS-CoV-2 antigen test has been expanded to include screening of asymptomatic individuals. This claim builds on its existing claim that covers use of the test in individuals suspected of having COVID-19 by their health care provider within 12 days of symptom onset. The test received EUA in August 2020.
Microbix expands pandemic test controls portfolio
December 2021—Microbix Biosystems has expanded its portfolio of quality assessment products to include controls that support PCR tests for four major variants of concern of SARS-CoV-2.